Literature DB >> 6653617

Comparative pharmacokinetic profiles of cinoxacin and pipemidic acid in humans.

J M Brogard, F Comte, J Lavillaureix.   

Abstract

Serum and urinary levels of Cinoxacin and pipemidic acid were determined at 7-day intervals in the same 10 healthy volunteers after a single oral dose of respectively 500 and 400 mg of the drugs. Comparison of results shows that Cinoxacin was absorbed faster (absorption half-life, ta 1/2cin = 0.25 h) than pipemidic acid (ta 1/2pip = 0.37 h) and distributed in a smaller apparent volume (AVDcin = 23.5 1/1.73 m2; AVDpip = 60.1 1/1.73 m2). Biological half-lives were identical (tb 1/2cin = 2.10 h; tb 1/2pip = 2.15 h). On the other hand, serum levels for Cinoxacin at 1, 2 and 4 hours (8.1 +/- 1.5 micrograms/ml, 10.6 +/- 1.5 micrograms/ml, 5.6 +/- 1.3 micrograms/ml respectively) were higher than those for pipemidic acid (3.3 +/- 0.3 micrograms/ml, 3.4 +/- 0.5 micrograms/ml, 2.1 +/- 0.5 micrograms/ml respectively). Urinary excretion of the two derivatives during the 12 hours following their administration was similar (Ucin0-12h = 86%; Upip0-12h = 83%). Mean urinary concentrations were particularly high, still attaining respectively 90 +/- 29 micrograms/ml and 131 +/- 38 micrograms/ml in samples collected between the 9th and the 12th hours; these levels were well above the M.I.C. for the Gram-negative organisms included within the spectrum of activity of these two quinolones. In addition, predictive calculations of serum levels reached after multiple dosing indicate that at an administration rate of 500 mg every 6 or preferably every 4 hours, Cinoxacin concentrations should be sufficiently high to be of interest in the treatment of systemic infections by sensitive organisms.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6653617     DOI: 10.1007/BF03188755

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  12 in total

1.  Pipemidic acid: absorption, distribution, and excretion.

Authors:  M Shimizu; S Nakamura; Y Takase; N Kurobe
Journal:  Antimicrob Agents Chemother       Date:  1975-04       Impact factor: 5.191

2.  Studies on cinoxacin. 1. In vitro activity of cinoxacin, as compared to nalidixic acid, against urinary tract pathogens.

Authors:  P A Mårdh; S Collen; K E Andersson
Journal:  J Antimicrob Chemother       Date:  1977-09       Impact factor: 5.790

3.  Compound 64716, a new synthetic antibacterial agent.

Authors:  W E Wick; D A Preston; W A White; R S Gordee
Journal:  Antimicrob Agents Chemother       Date:  1973-10       Impact factor: 5.191

4.  Antibacterial activity of cinoxacin in vitro.

Authors:  H Giamarellou; G G Jackson
Journal:  Antimicrob Agents Chemother       Date:  1975-05       Impact factor: 5.191

5.  Studies on cinoxacin. 3. Concentrations of cinoxacin in serum, urine and tissues of urological patients.

Authors:  S Colleen; K E Andersson; P A Mårdh
Journal:  J Antimicrob Chemother       Date:  1977-11       Impact factor: 5.790

6.  [Spectrofluorimetric analysis of pipemidic acid in biological fluids. Digestive absorption and urinary elimination in the rat, rabbit, dog and man].

Authors:  G Montay; M Vigouroux; F Roquet; M Reynier
Journal:  Therapie       Date:  1977 Sep-Oct       Impact factor: 2.070

7.  Pharmacology of cinoxacin in humans.

Authors:  H R Black; K S Israel; R L Wolen; G L Brier; B D Obermeyer; E A Ziege; J D Wolny
Journal:  Antimicrob Agents Chemother       Date:  1979-02       Impact factor: 5.191

8.  Cinoxacin: pharmacokinetics and the effect of probenecid.

Authors:  K S Israel; H R Black; R L Nelson; M K Brunson; J F Nash; G L Brier; J D Wolney
Journal:  J Clin Pharmacol       Date:  1978-10       Impact factor: 3.126

9.  Cinoxacin: pharmacokinetics and tolerance in patients with normal and impaired renal function.

Authors:  S Maigaard; N Frimodt-Möller; P G Welling; P O Madsen
Journal:  Antimicrob Agents Chemother       Date:  1979-09       Impact factor: 5.191

10.  Cinoxacin concentrations in plasma, urine and prostatic tissue after oral administration to man.

Authors:  R A Burt; T Morgan; J P Payne; R M Bonner
Journal:  Br J Urol       Date:  1977-04
View more
  5 in total

1.  Single- and multiple-dose pharmacokinetics of pipemidic acid in normal human volunteers.

Authors:  E Klinge; P T Männistö; R Mäntylä; J Mattila; U Hänninen
Journal:  Antimicrob Agents Chemother       Date:  1984-07       Impact factor: 5.191

2.  Comparison of high-pressure liquid chromatography and microbiological assay for the determination of biliary elimination of ciprofloxacin in humans.

Authors:  J M Brogard; F Jehl; H Monteil; M Adloff; J F Blickle; P Levy
Journal:  Antimicrob Agents Chemother       Date:  1985-08       Impact factor: 5.191

3.  Ciprofloxacin biliary disposition in cholecystectomised patients with special references to HPLC and bioassay data.

Authors:  F Jehl; M Adloff; H Monteil; J M Brogard
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1987 Apr-Jun       Impact factor: 2.441

4.  Pharmacokinetics: metabolism and renal excretion of quinolones in man.

Authors:  T B Vree; W J Wijnands; P J Guelen; A M Baars; Y A Hekster
Journal:  Pharm Weekbl Sci       Date:  1986-02-21

Review 5.  Piperazine based antimicrobial polymers: a review.

Authors:  Manohara Dhulappa Jalageri; Akshatha Nagaraja; Yashoda Malgar Puttaiahgowda
Journal:  RSC Adv       Date:  2021-04-23       Impact factor: 3.361

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.